A double-blind placebo controlled randomized phase III trial of Fulvestrant and Ipatasertib as treatment for advanced HER-2 Negative and Estrogen Receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor (FINER).

  • Moore, Maggie (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date14/02/22 → 31/12/26

Keywords

  • Medical oncology
  • Breast cancer
  • Clinical trial